Изчислете точни обеми за реконституция, инсулинови единици и дози на флакон за всеки пептид.
CJC-1295 No DAC (without Drug Affinity Complex) is a synthetic analog of endogenous Growth Hormone-Releasing Hormone (GHRH). By binding to pituitary GHRH receptors, it stimulates natural, pulsatile growth hormone secretion. This guide covers everything you need to know: mechanism of action, dosing, reconstitution, storage, side effects, and how to combine it effectively with peptides like Ipamorelin.
Medical Disclaimer: The content on this page is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Peptides are not approved drugs for human use. Always consult a qualified healthcare provider before using peptides.
CJC-1295 No DAC — also called Modified GRF(1-29) or Mod GRF 1-29 — is a 29-amino-acid peptide derived from the first 29 residues of native GHRH. Four strategic amino acid substitutions (at positions 2, 8, 15, and 27) protect it from dipeptidyl peptidase IV (DPP-IV) enzymatic cleavage, increasing stability and receptor binding affinity compared to native GHRH while preserving the short, pulsatile pattern of GH release.
The key distinction from CJC-1295 with DAC is the absence of the Drug Affinity Complex. Without DAC, the peptide cannot covalently bind albumin in the bloodstream, resulting in a half-life of approximately 30 minutes rather than 6–8 days. This shorter half-life produces discrete GH pulses that more closely mirror the body's natural ultradian rhythm — a property many researchers consider more physiologically appropriate.
CJC-1295 No DAC binds to the GHRH receptor on somatotroph cells in the anterior pituitary. Receptor activation triggers intracellular cAMP signaling, leading to GH synthesis and release. The released GH then stimulates hepatic production of IGF-1 (Insulin-like Growth Factor 1), which mediates many of the downstream anabolic and lipolytic effects.
Potential effects mediated by increased GH and IGF-1 include:
Accurate dosage calculation is critical for both efficacy and safety. The standard dosing parameters for CJC-1295 No DAC are:
The standard BergdorfBio vial contains 2 mg of lyophilized CJC-1295 No DAC. Adding 2 ml of bacteriostatic water (BAC water) gives a concentration of:
2 mg ÷ 2 ml = 1 mg/ml = 1,000 mcg/ml
Using a standard U100 insulin syringe (100 units = 1 ml):
At 200 mcg twice daily, one 2 mg vial lasts 5 days. At 100 mcg once daily, the same vial lasts 20 days.
For precise volume calculations based on your vial size, reconstitution volume, and target dose, use the BergdorfBio Peptide Calculator. Enter your vial parameters and desired dose to get the exact volume to draw.
Start with a single 100 mcg injection in the evening, 30–60 minutes before sleep, on an empty stomach. This approach takes advantage of the natural nocturnal GH pulse and allows you to assess individual tolerance over the first 1–2 weeks before increasing frequency or dose.
The most widely used protocol consists of two daily injections:
Insulin strongly suppresses GH release, so timing injections away from meals — especially carbohydrate-rich meals — is essential. For those combining with Ipamorelin, both peptides can be drawn into the same syringe and injected together.
Experienced users may add a third injection at midday, fasted or at least 2 hours post-meal. Three daily injections provide more sustained IGF-1 elevation throughout the day but require stricter meal timing discipline.
Typical cycles run 8–12 weeks followed by a 4-week break. Some users report sustained benefits with longer 3–6 month cycles, though long-term human data remains limited. Cycle breaks help prevent desensitization of pituitary GHRH receptors.
CJC-1295 No DAC is supplied as a lyophilized (freeze-dried) powder and must be reconstituted before injection. You will need:
Use only bacteriostatic water or sterile water for injection. Do not use tap water, distilled water from consumer bottles, or saline solution not intended for injection.
CJC-1295 No DAC has a well-established tolerability profile when used at recommended doses. Known and potential side effects include:
Discontinue immediately and consult a physician if you experience persistent swelling, severe headache, visual disturbances, joint pain, or any other concerning symptoms. CJC-1295 No DAC is contraindicated in individuals with active malignancies, pituitary disorders, insulin resistance/diabetes (without medical supervision), or pregnancy.
The combination of CJC-1295 No DAC with Ipamorelin is the most widely studied and used GHRH/GHRP protocol. The synergy arises from complementary mechanisms: CJC-1295 activates the GHRH receptor, while Ipamorelin activates the ghrelin receptor (GHS-R1a). Simultaneous activation of both pathways produces a substantially larger GH pulse than either peptide alone.
Ipamorelin is particularly valued in this stack because it does not significantly raise cortisol or prolactin levels — a key advantage over older GHRPs like GHRP-2 or GHRP-6. The two peptides are fully compatible and can be mixed in the same syringe.
For individuals primarily targeting fat loss and body recomposition, AOD-9604 (a lipolytic GH fragment) can be added. AOD-9604 acts directly on adipocytes to promote fat breakdown without stimulating systemic GH or IGF-1 levels, making the combination complementary rather than redundant.
CJC-1295 with DAC contains a Drug Affinity Complex that enables covalent albumin binding, extending its half-life to 6–8 days. This allows for once-weekly injections but produces a sustained, blunted GH elevation rather than discrete pulses. CJC-1295 No DAC has a ~30-minute half-life and produces more physiological, pulsatile GH release. Most research protocols and practitioners favor the No DAC version for its more natural GH profile.
Yes. Both peptides are chemically compatible. Draw one peptide into the insulin syringe first, then add the second. Inject subcutaneously immediately after mixing. Do not store pre-mixed peptides.
The two most effective windows are: (1) morning, immediately upon waking before any food or carbohydrate intake; and (2) approximately 30–60 minutes before sleep. Both windows coincide with naturally low insulin levels, which maximize pituitary GH responsiveness. Avoid injecting within 2 hours of a carbohydrate-heavy meal.
Most users notice improved sleep quality and faster exercise recovery within 3–4 weeks. Observable changes in body composition — increased muscle definition, reduced subcutaneous fat — typically emerge after 8–12 weeks. This timeline reflects the gradual rise and sustained elevation of IGF-1 required for tissue-level changes.
Unlike synthetic GH administration, CJC-1295 No DAC works by amplifying the pituitary's existing capacity to produce and release GH — it does not introduce exogenous GH. Most research suggests that properly cycled GHRH analogs do not suppress the hypothalamic-pituitary axis, though prolonged continuous use theoretically risks receptor desensitization. Cycling is recommended as a precaution.
It is strongly recommended to establish baseline IGF-1 levels and rule out contraindications before starting any GHRH analog. A physician can also monitor IGF-1 during a cycle to ensure levels remain in a safe, physiological range. Elevated IGF-1 beyond normal ranges is associated with adverse health risks.
BergdorfBio offers research-grade CJC-1295 No DAC with verified purity. Each vial is tested for identity and concentration. Visit the CJC-1295 No DAC product page for current availability and pricing.
The legal status of CJC-1295 No DAC varies by jurisdiction. In most countries it is not approved for human pharmaceutical use and is classified as a research chemical. It is prohibited in competitive sports under WADA regulations. Always verify the regulations applicable in your country before purchasing or using this peptide.
Disclaimer: This content is for informational and research purposes only. CJC-1295 No DAC is not an approved drug for human therapeutic use. The applications described have not been evaluated or approved by the FDA, EMA, or any other regulatory authority. Do not use peptides without the supervision of a qualified medical professional.
Вижте продукта
CJC-1295 (без DAC)